CVS (CVS) could benefit from changes in the way the government pays for kidney disease treatment, Reuters reports. The proposed changes would favor lower cost home treatment, an area where CVS has been making a significant push, and that the change could present a risk to dialysis clinic operators DaVita (DVA) and Fresenius Medical Care (FMS)
https://thefly.com/landingPageNews.php?id=2873621
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.